Replies to post #102245 on Biotech Values

[oc631]

No—I think the FDA will ask VRTX and MRK to investigate the relevance of IL-28B variants as part of the companies’ post-marketing commitments.

I wonder how long VRTX knew about the CC variant before the study was released? They sure did a lot of testing in New Zealand.